TGFB1 and neoplasm: In vivo studies validated that Ds@ACTE significantly downregulated the TGF‐β expression to reprogram the immunosuppressive microenvironment, and thereby reinforce the chemotherapeutic effect of DOX and DOX‐induced anti‐tumor immune response.